ALAVERT D-12 HOUR OTC
Generic Name and Formulations:
Loratadine 5mg, pseudoephedrine sulfate 120mg; ext-rel tabs.
Indications for ALAVERT D-12 HOUR:
Seasonal allergic rhinitis with nasal congestion.
Swallow whole. 1 tab every 12 hrs.
Narrow-angle glaucoma. Urinary retention. Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hepatic or renal impairment. Hypertension. Ischemic heart disease. Increased intraocular pressure. Thyroid disease. GI or GU obstruction. Seizures. Diabetes. Pregnancy (Cat.B). Nursing mothers: not recommended.
See Contraindications. Pseudoephedrine: Antagonizes antihypertensives. Increased ectopic pacemaker activity with digitalis.
Antihistamine + sympathomimetic.
Dry mouth, insomnia, somnolence, nervousness, dizziness, dyspepsia, pharyngitis, anorexia, bronchospasm.
Loratadine: Hepatic (CYP3A4, 2D6); Pseudoephedrine: incompletely metabolized (less than 1%).
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States